MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the... AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.
- Mechanism
- Curator reviewed
MPI-674 is an aromatase inhibitor (AI). It reduces the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.
- Primary indication
- Investigated for use/treatment in menstrual disorders.Curator reviewed
- Code names
- MPI-674
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with MPI-674, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account